A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease-pilot study

Background Donepezil Hydrochloride (Aricept) is a selective anticholinesterase inhibitor developed for the treatment of Alzheimer's disease (AD). This study investigated the safety and efficacy of the drug to treat Down syndrome (DS) adults with mild to moderate AD. Method This was a 24‐week, d...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of geriatric psychiatry 2002-03, Vol.17 (3), p.270-278
Hauptverfasser:	Prasher, Vee. P., Huxley, Adam, Haque, M. S.
Format:	Artikel
Sprache:	eng
Schlagworte:	acetylcholinesterase inhibitors Adult Aged Alzheimer Disease - diagnosis Alzheimer Disease - drug therapy Alzheimer Disease - psychology Biological and medical sciences Cholinesterase Inhibitors - adverse effects Cholinesterase Inhibitors - therapeutic use Chromosome aberrations Comorbidity Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases dementia donepezil Double-Blind Method Down syndrome Down Syndrome - diagnosis Down Syndrome - drug therapy Down Syndrome - psychology drug trial Female Humans Indans - adverse effects Indans - therapeutic use Male Medical genetics Medical sciences Middle Aged Neurology Nootropic Agents - adverse effects Nootropic Agents - therapeutic use Pilot Projects Piperidines - adverse effects Piperidines - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!